Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...

Mathematicians love the certainty of proofs. This is how they verify that their intuition matches observable truth.

Good day, and welcome to the Vertex Pharmaceuticals First Quarter 2025 Earnings Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...

Immersive training devices from Vertex Solutions are destined for the U.S. Air Force for the Fighter Bomber Fundamentals program. [Courtesy: Vertex Solutions] Vertex Solutions, a small business ...

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter results that fell short of analyst expectations, sending shares down 2.8% in after-hours trading on Monday.

Vertex Inc.: Vertex to Announce First Quarter 2025 Financial Results on Wednesday, May 7, 2025 Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . FNRD-2.627.0 ...